FOUND RESULTS 230

Companies (230)

Theravance Biopharma

  • C2B - Patient to Business
Theravance Biopharma is a diversified biopharmaceutical company with the core purpose of creating medicines that make a difference in the lives of patients suffering from serious illness.

MeiraGTx

  • C2B - Patient to Business
MeiraGTx is committed to the development of novel gene therapies to transform the lives of patients suffering from acquired and inherited disorders. They are developing innovative gene therapies for ocular diseases including rare inherited blindness and age-related macular degeneration (AMD).

CTI BioPharma

  • C2B - Patient to Business
CTI BioPharma is a biopharmaceutical company whose mission is to acquire, develop and bring to market less toxic, more effective therapies to treat and cure cancer. Our therapeutic focus is on novel targeted therapies covering a spectrum of blood-related cancers. We see patients as people, looking at potential therapies from the patient’s perspective to address both the clinical need and the impact treatment can have on a patient’s life. We prioritize the patient experience and are committed to developing therapeutic options for people living with cancer who want a chance at a longer and better quality of life.

Cerevast Therapeutics

  • C2B - Patient to Business
Cerevast is a medical technology company based in Redmond, Washington, USA, that develops medical products for the treatment of neurologic disorders.Cerevast is also using transcranial ultrasound (TUS) to improve long term clinical outcomes for stroke patients. T

Cascadian Therapeutics

  • C2B - Patient to Business
Cascadian Therapeutics is a biotechnology company dedicated to the development of oncology products that can improve the lives and outcomes of cancer patients. Our goal is to discover, develop and commercialize novel compounds that have the potential to improve the lives and outcomes of cancer patients. Our most advanced product candidate is tucatinib (ONT-380), an orally active and selective small molecule HER2 inhibitor. We are also developing a Chk1 inhibitor as a preclinical product candidate.

Adaptive Biotechnologies

  • C2B - Patient to Business
Adaptive is at the forefront of immune-based discoveries, combining high-throughput sequencing and expert bioinformatics to profile T-cell and B-cell receptors. We bring the accuracy and sensitivity of our immunosequencing platform into laboratories around the world to drive groundbreaking research in cancer and other immune-mediated diseases. Adaptive also translates immunosequencing discoveries into clinical diagnostics and therapeutic development to improve patient care.

Blaze Bioscience

  • C2B - Patient to Business
Blaze Bioscience, Inc. is a privately held biotechnology company focused on guided therapies. Blaze was founded in 2010 by Dr. Jim Olson, a pediatric neuro-oncologist at the Fred Hutchinson Cancer Research Center and Seattle Children’s Hospital, and Heather Franklin, a former senior business executive from ZymoGenetics. Blaze is working to develop Tumor Paint products and Optide*-based guided therapeutics. Blaze is focused on guided therapies and is working to develop Tumor Paint products and Optide-based guided therapeutics for patients.

Biotronik

  • C2B - Patient to Business
At BIOTRONIK, they are committed to helping people with heart and blood vessel diseases live healthy, fulfilling lives. This immense responsibility motivates thousands of employees worldwide to develop new cardiovascular and endovascular medical technologies that physicians trust to save and improve patient lives. Their unique, safe and reliable products, including pacemakers, stents, implantable defibrillators and remote monitoring services, help patients in more than 100 countries.

Shire Regenerative Medicine

  • C2B - Patient to Business
Shire is now the leading global biotechnology company focused on serving people affected by rare diseases and highly specialized conditions. These diseases are often misunderstood, under-diagnosed, and potentially life-threatening. At Shire, we are dedicated to expanding, building and sustaining leadership across our key therapeutic areas through our extensive portfolio of products, innovative pipeline and collaborative approach to working with diverse partners around the globe. We strive to earn and keep the trust of our patients, their families and physicians, and all others who support and advance their care.

Sangamo BioSciences

  • C2B - Patient to Business
Sangamo Therapeutics, science is a means to develop new medicines with the potential to transform the lives of patients living with serious genetic diseases. The Company’s scientists are leaders in the discovery, research and development of technologies enabling gene-based therapeutic development. Sangamo expects its scientific investment will reliably generate new programs for human clinical development.

Renova Therapeutics

  • C2B - Patient to Business
Renova Therapeutics is working to create a portfolio of definitive one-time gene therapy treatments as well as peptide infusion therapies to restore health to people suffering from cardiovascular and metabolic diseases. The first indications the company is pursuing are gene therapies for congestive heart failure (CHF) and type 2 diabetes, two of the most common and devastating chronic diseases in the world. Along with single-dose gene therapies, Renova Therapeutics is also developing a peptide infusion treatment for the periods in which CHF patients are hospitalized for Acute Decompensated Heart Failure.

Prima BioMed

  • C2B - Patient to Business
Prima BioMed (ASX:PRR, NASDAQ: PBMD) is a globally active biotechnology company that is striving to become a leader in the development of immunotherapeutic products. With operations based in Australia, Germany and France, Prima BioMed is dedicated to bringing innovative treatment options to market for patients and to maximizing value for shareholders.

Northwest Biotherapeutics

  • C2B - Patient to Business
NW Bio is developing cancer vaccines designed to treat a broad range of solid tumor cancers more effectively than current treatments, and without the side effects of chemotherapy drugs. NW Bio’s proprietary manufacturing technology enables the Company to produce its personalized vaccine in an efficient, cost-effective manner.

Juventas Therapeutics

  • C2B - Patient to Business
Juventas Therapeutics is a private, clinical stage biotechnology company developing novel non-viral gene therapies that activate natural processes to repair the body. Our product candidate, JVS-100, is a non-viral gene therapy that expresses stromal cell-derived factor-1, or SDF-1, a naturally occurring signaling protein that has been shown to recruit the body’s own stem cells and promote tissue repair in a broad range of disease states. Juventas’ therapeutic approach is based on research originating at the Cleveland Clinic. Juventas is currently enrolling a Phase 2b study in patients with advanced peripheral artery disease.

Baxter

  • C2B - Patient to Business
Baxter’s Hospital Products business manufactures products used in the delivery of fluids and drugs to patients across the continuum of care. These include IV and other sterile solutions and administration sets, premixed drugs and drug-reconstitution systems, IV nutrition products, infusion pumps, and inhalation anesthetics. The business also provides products and services related to pharmacy compounding, drug formulation, and packaging technologies.

Get our newsletter for the latest news & updates.

Share the knowledge: